• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

CPAP Preferentially Improves Cardiovascular Outcomes in High-Risk OSA

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 6, 2025.

WEDNESDAY, Aug. 6, 2025 -- In patients with high-risk obstructive sleep apnea (OSA), continuous positive airway pressure (CPAP) improves cardiovascular outcomes, while harm may be seen in those with low-risk OSA, according to a study published online Aug. 5 in the European Heart Journal.

Ali Azarbarzin, Ph.D., from Harvard Medical School in Boston, and colleagues conducted a post-hoc analysis of randomized trials to examine whether the cardiovascular benefit of CPAP occurs preferentially in high-risk OSA, characterized by greater OSA-related heart rate acceleration or hypoxemia. The researchers examined the CPAP treatment effect on major adverse cardiovascular and cerebrovascular events (MACCE) for high-risk OSA and evaluated the difference versus low-risk OSA.

Overall, 16.6 and 16.3 percent of participants reached the MACCE end point with CPAP and usual care (1,778 and 1,771 participants, respectively). The researchers found that for participants with versus without high-risk OSA, the CPAP treatment effect was greater (interaction hazard ratio, 0.69). A stronger differential effect was seen for those without excessive sleepiness or without increased blood pressure (interaction hazard ratios, 0.59 and 0.54, respectively). Benefits of CPAP in high-risk OSA were seen alongside harm for those with low-risk OSA.

"For clinicians and policymakers, this means we may need to rethink current guidelines for treating nonsleepy patients and consider focusing treatment for cardiovascular risk reduction on those who stand to gain the most," Azarbarzin said in a statement. "We also need to be cautious about using CPAP in people who don't have high-risk markers, as they may not benefit and could even be harmed."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.